

## **SARS-CoV-2-RNA viremia is linked to immunological dysregulation and critical illness in COVID-19**

Jesús F Bermejo-Martin, Milagros González-Rivera, Raquel Almansa, Dariela Micheloud, Marta Domínguez-Gil, Salvador Resino, Marta Martín-Fernández, Pablo Ryan, Felipe Pérez-García, Luis Tamayo, Raúl Lopez-Izquierdo, Elena Bustamante, César Aldecoa, José Manuel Gómez, Jesús Rico-Feijoo, Antonio Orduña, Raúl Méndez, Isabel Fernández Natal, Gregoria Megías, Montserrat González-Estecha, Demetrio Carriedo, Cristina Doncel, Noelia Jorge, Félix del Campo José Antonio Fernández-Ratero, Wysali Trapiello, Paula González-Jiménez, Guadalupe Ruiz, Alyson A. Kelvin, Ali Toloue Ostadgavahi, Ruth Oneizat, Luz María Ruiz, Iria Miguéns, Esther Gargallo, Ioana Muñoz, Sara Pelegrin, Silvia Martín, Pablo García Olivares, Jamil Antonio Cedeño, Tomás Ruiz Albi, Carolina Puertas, Jose Ángel Berezo, Gloria Renedo, Rubén Herrán, Juan Bustamante-Munguira, Pedro Enríquez, Ramón Cicuendez, Jesús Blanco, Jesica Abadia, Julia Gómez Barquero, Nuria Mamolar, Natalia Blanca-López, Luis Jorge Valdivia, Belén Fernández Caso, María Ángeles Mantecón, Anna Motos, Laia Fernandez-Barat, Ricard Ferrer, Ferrán Barbé, Antoni Torres, Rosario Menéndez, José María Eiros, David J Kelvin

### **Online Data Supplement**

| Hospital   | Outpatients | Wards | ICU |
|--|-------------|-------|-----|
| Hospital Clínico Universitario de Valladolid             | 0           | 0     | 45  |
| Hospital General Universitario Gregorio Marañón (Madrid) | 44          | 4     | 25  |
| Hospital Universitario Infanta Leonor (Madrid)           | 0           | 30    | 0   |
| Hospital Universitario y Politécnico de La Fe (Valencia) | 0           | 27    | 0   |
| Hospital Universitario Río Hortega (Valladolid)          | 2           | 22    | 23  |
| Hospital Universitario Príncipe de Asturias (Madrid)     | 4           | 17    | 1   |
| Hospital Universitario de Burgos                         | 0           | 0     | 2   |
| Hospital Universitario de León                           | 0           | 0     | 4   |
| Total  | 50          | 100   | 100 |

**Table E1:** Patients` by participant hospital.

|  |   | Outpatients (1) | Ward (2) | ICU (3) |
|--|---|-----------------|----------|---------|
| <b>Characteristics</b>                           | Age [years, median]                     | 0               | 0        | 0       |
|  | Male                                    | 0               | 0        | 0       |
| <b>Comorbidities, [% (n)]</b>                    | Alcoholism                              | 0               | 0        | 0       |
|  | Smoking                                 | 0               | 0        | 0       |
|  | Drug abuse                              | 0               | 0        | 0       |
|  | Chronic cardiac disease                 | 0               | 0        | 0       |
|  | Chronic vascular disease                | 0               | 0        | 0       |
|  | Chronic obstructive pulmonary disease   | 0               | 0        | 0       |
|  | Asthma                                  | 0               | 0        | 0       |
|  | Obesity                                 | 0               | 0        | 0       |
|  | Hypertension                            | 0               | 0        | 0       |
|  | Dyslipidemia                            | 0               | 0        | 0       |
|  | Chronic renal failure                   | 0               | 0        | 0       |
|  | Chronic hepatic failure                 | 0               | 0        | 0       |
|  | Neurological disease                    | 0               | 0        | 0       |
|  | HIV                                     | 0               | 0        | 0       |
|  | Autoimmune disease                      | 0               | 0        | 0       |
|  | Chronic intestinal inflammatory disease | 0               | 0        | 0       |
|  | Type 1 diabetes                         | 0               | 0        | 0       |
|  | Type 2 diabetes                         | 0               | 0        | 0       |
|  | Cancer                                  | 0               | 0        | 0       |
| <b>Treatment during hospitalization, [% (n)]</b> | Invasive mechanical ventilation         | 0               | 0        | 0       |
|  | Non-invasive mechanical ventilation     | 0               | 7        | 0       |
|  | Hydroxychloroquine                      | 1               | 0        | 0       |
|  | Chloroquine                             | 1               | 0        | 0       |
|  | Corticoids                              | 5               | 2        | 0       |
|  | Azithromycin                            | 6               | 1        | 0       |
|  | Remdesivir                              | 0               | 0        | 0       |
|  | Tocilizumab                             | 0               | 0        | 0       |
|  | Kaletra                                 | 0               | 1        | 0       |
| Beta Interferon                                  | 0                                       | 0               | 1        |         |
| <b>Time course and outcome</b>                   | Length of hospital stay                 | -               | 1        | 6       |
|  | RNAemia                                 | 0               | 0        | 0       |
|  | SARS-CoV-2 IgG                          | 0               | 0        | 0       |
|  | Hospital mortality                      | 0               | 0        | 0       |
| <b>Measurements at diagnosis</b>                 | Temperature (°C)                        | 0               | 0        | 2       |
|  | Systolic Arterial Pressure (mmHg)       | 3               | 1        | 1       |
|  | Oxygen saturation (%)                   | 0               | 1        | 3       |
|  | Pulmonary infiltrate                    | 0               | 0        | 0       |
|  | Bilateral pulmonary infiltrate          | 0               | 0        | 0       |
|  | Glucose (mg/dl)                         | 0               | 2        | 0       |
| Creatinine (mg/dl)                               | 0                                       | 0               | 0        |         |

|                                  |                                      |    |    |    |
|----------------------------------|--------------------------------------|----|----|----|
| <b>Measurements at diagnosis</b> | <b>Na (mEq/L)</b>                    | 0  | 0  | 0  |
|                                  | <b>K (mEq/L)</b>                     | 0  | 0  | 0  |
|                                  | <b>Platelet count (cell/mm3)</b>     | 0  | 0  | 0  |
|                                  | <b>INR</b>                           | 3  | 14 | 3  |
|                                  | <b>D Dimer (ng/ml)</b>               | 0  | 0  | 0  |
|                                  | <b>LDH (UI/L)</b>                    | 11 | 2  | 5  |
|                                  | <b>GPT (UI/L)</b>                    | 2  | 0  | 14 |
|                                  | <b>Ferritin (pg/ml)</b>              | 0  | 0  | 0  |
|                                  | <b>C-reactive protein (mg/dl)</b>    | 3  | 0  | 13 |
|                                  | <b>Hematocrit (%)</b>                | 0  | 0  | 0  |
|                                  | <b>White Blood cells (cells/mm3)</b> | 0  | 0  | 0  |
|                                  | <b>Lymphocytes (cells/mm3) [</b>     | 0  | 0  | 0  |
|                                  | <b>Neutrophils (cells/mm3)</b>       | 0  | 0  | 1  |
|                                  | <b>Monocytes (cells/mm3)</b>         | 1  | 0  | 1  |
|                                  | <b>Eosinophils (cells/mm3)</b>       | 0  | 0  | 0  |
| <b>Basophils (cells/mm3)</b>     | 0                                    | 0  | 0  |    |

**Table E2:** Missing values in the study variables

|                  |           |          | <b>CI 95%</b> |              |
|------------------|-----------|----------|---------------|--------------|
|                  | <b>OR</b> | <i>p</i> | <b>lower</b>  | <b>upper</b> |
| Viremia          | 8.24      | < 0.001  | 4.71          | 14.41        |
| Age              | 1.03      | 0.01     | 1.01          | 1.05         |
| Sex              | 1.56      | 0.08     | 0.94          | 2.58         |
| Obesity          | 1.59      | 0.16     | 0.82          | 3.08         |
| Hypertension     | 0.98      | 0.95     | 0.56          | 1.73         |
| Type II Diabetes | 1.42      | 0.33     | 0.70          | 2.87         |
| Cardiac disease  | 0.77      | 0.56     | 0.32          | 1.87         |
| Asthma           | 0.61      | 0.38     | 0.20          | 1.85         |
| Dyslipidemia     | 1.03      | 0.91     | 0.57          | 1.88         |

**Table E3:** Multivariate ordinal logistic regression analysis to assess the association between viremia and the three severity categories (outpatients, wards and ICU).

| Unadjusted              |      |      |       |        |       |         |      |     |       | Adjusted                |      |      |       |        |       |         |      |     |       |
|-------------------------|------|------|-------|--------|-------|---------|------|-----|-------|-------------------------|------|------|-------|--------|-------|---------|------|-----|-------|
| VIREMIA                 | AMR  | se   | z     | pvalue | low I | upper I | PsR2 | N°  | FDR   | VIREMIA                 | AMR  | se   | z     | pvalue | low I | upper I | PsR2 | N°  | FDR   |
| LDH UI/L                | 1,70 | 0,11 | 8,16  | <0,001 | 1,50  | 1,93    | 0    | 232 | 0,000 | LDH UI/L                | 1,36 | 0,08 | 5,63  | <0,001 | 1,22  | 1,52    | 0    | 232 | 0,000 |
| Lymphocytes (cell/mm3)  | 0,62 | 0,04 | -6,81 | <0,001 | 0,54  | 0,71    | 0    | 250 | 0,000 | Lymphocytes (cell/mm3)  | 0,79 | 0,07 | -2,79 | 0,005  | 0,68  | 0,93    | 0    | 250 | 0,015 |
| Neutrophils (cell/mm3)  | 1,32 | 0,10 | 3,75  | 0,000  | 1,14  | 1,53    | 0    | 249 | 0,000 | Neutrophils (cell/mm3)  | 1,07 | 0,08 | 0,88  | 0,377  | 0,92  | 1,25    | 0    | 249 | 0,480 |
| Monocytes (cell/mm3)    | 0,71 | 0,05 | -4,80 | 0,000  | 0,61  | 0,81    | 0    | 248 | 0,000 | Monocytes (cell/mm3)    | 0,79 | 0,07 | -2,84 | 0,005  | 0,67  | 0,93    | 0    | 248 | 0,014 |
| Platelets cellsx10^3_uL | 0,84 | 0,05 | -3,26 | 0,001  | 0,76  | 0,93    | 0    | 250 | 0,002 | Platelets cellsx10^3_uL | 0,83 | 0,04 | -3,41 | 0,001  | 0,75  | 0,93    | 0    | 250 | 0,004 |
| INR                     | 1,02 | 0,06 | 0,32  | 0,747  | 0,91  | 1,13    | 0    | 230 | 0,837 | INR                     | 0,99 | 0,04 | -0,32 | 0,752  | 0,92  | 1,07    | 0    | 230 | 0,849 |
| CRP (mg/dl)             | 2,09 | 0,37 | 4,19  | 0,000  | 1,48  | 2,95    | 0    | 234 | 0,000 | CRP (mg/dl)             | 1,36 | 0,25 | 1,62  | 0,105  | 0,94  | 1,96    | 0    | 234 | 0,154 |
| O2 saturation           | 0,96 | 0,01 | -5,24 | <0,001 | 0,94  | 0,97    | 0    | 246 | 0,000 | O2 saturation           | 0,97 | 0,01 | -3,66 | 0,000  | 0,95  | 0,99    | 0    | 246 | 0,002 |
| GPT (UI/L)              | 1,40 | 0,19 | 2,48  | 0,013  | 1,07  | 1,82    | 0    | 234 | 0,019 | GPT (UI/L)              | 1,16 | 0,16 | 1,11  | 0,265  | 0,89  | 1,52    | 0    | 234 | 0,371 |
| Creatinin (mg/dl)       | 0,98 | 0,10 | -0,21 | 0,833  | 0,80  | 1,20    | 0    | 250 | 0,864 | Creatinin (mg/dl)       | 0,84 | 0,08 | -1,89 | 0,059  | 0,71  | 1,01    | 0    | 250 | 0,104 |
| G-CSF                   | 1,75 | 0,26 | 3,78  | 0,000  | 1,31  | 2,34    | 0    | 250 | 0,000 | G-CSF                   | 1,66 | 0,25 | 3,30  | 0,001  | 1,23  | 2,23    | 0    | 250 | 0,004 |
| IL-1b                   | 1,05 | 0,22 | 0,24  | 0,809  | 0,70  | 1,59    | 0    | 250 | 0,864 | IL-1b                   | 1,06 | 0,19 | 0,31  | 0,758  | 0,75  | 1,49    | 0    | 250 | 0,849 |
| D-DIMER                 | 2,06 | 0,55 | 2,68  | 0,007  | 1,21  | 3,48    | 0    | 250 | 0,012 | D-DIMER                 | 1,06 | 0,31 | 0,20  | 0,843  | 0,60  | 1,89    | 0    | 250 | 0,874 |
| FERRITIN                | 1,69 | 0,23 | 3,87  | 0,000  | 1,29  | 2,20    | 0    | 250 | 0,000 | FERRITIN                | 1,38 | 0,17 | 2,62  | 0,009  | 1,08  | 1,76    | 0    | 250 | 0,021 |
| IL-10                   | 3,62 | 0,69 | 6,75  | <0,001 | 2,49  | 5,26    | 0    | 250 | 0,000 | IL-10                   | 2,26 | 0,46 | 4,02  | 0,000  | 1,52  | 3,36    | 0    | 250 | 0,001 |
| IL-17A                  | 1,75 | 0,58 | 1,70  | 0,090  | 0,92  | 3,36    | 0    | 250 | 0,115 | IL-17A                  | 1,54 | 0,35 | 1,93  | 0,054  | 0,99  | 2,39    | 0    | 250 | 0,100 |
| GM-CSF                  | 1,72 | 0,36 | 2,61  | 0,009  | 1,15  | 2,59    | 0    | 250 | 0,014 | GM-CSF                  | 1,37 | 0,24 | 1,76  | 0,078  | 0,97  | 1,93    | 0    | 250 | 0,121 |
| IL-7                    | 1,36 | 0,20 | 2,08  | 0,037  | 1,02  | 1,80    | 0    | 250 | 0,050 | IL-7                    | 1,08 | 0,19 | 0,47  | 0,638  | 0,78  | 1,51    | 0    | 250 | 0,777 |
| CXCL-10                 | 2,79 | 0,28 | 10,09 | <0,001 | 2,29  | 3,40    | 0    | 250 | 0,000 | CXCL-10                 | 2,25 | 0,25 | 7,27  | <0,001 | 1,81  | 2,80    | 0    | 250 | 0,000 |
| IL-1ra                  | 2,88 | 0,67 | 4,54  | 0,000  | 1,82  | 4,54    | 0    | 250 | 0,000 | IL-1ra                  | 1,90 | 0,42 | 2,87  | 0,004  | 1,23  | 2,94    | 0    | 250 | 0,014 |
| IL-6                    | 3,61 | 1,04 | 4,47  | 0,000  | 2,06  | 6,33    | 0    | 250 | 0,000 | IL-6                    | 1,31 | 0,36 | 0,97  | 0,332  | 0,76  | 2,24    | 0    | 250 | 0,443 |
| CCL-2                   | 2,51 | 0,37 | 6,26  | <0,001 | 1,88  | 3,35    | 0    | 250 | 0,000 | CCL-2                   | 1,54 | 0,21 | 3,17  | 0,002  | 1,18  | 2,01    | 0    | 250 | 0,006 |
| IL-12p70                | 1,00 | 0,09 | 0,02  | 0,981  | 0,84  | 1,19    | 0    | 250 | 0,981 | IL-12p70                | 1,01 | 0,08 | 0,14  | 0,885  | 0,87  | 1,17    | 0    | 250 | 0,885 |

|       |      |      |       |       |      |      |   |     |       |       |      |      |       |       |      |      |   |     |       |
|-------|------|------|-------|-------|------|------|---|-----|-------|-------|------|------|-------|-------|------|------|---|-----|-------|
| IL-2  | 1,27 | 0,21 | 1,46  | 0,145 | 0,92 | 1,74 | 0 | 250 | 0,170 | IL-2  | 1,03 | 0,17 | 0,20  | 0,838 | 0,75 | 1,42 | 0 | 250 | 0,874 |
| IL-4  | 0,75 | 0,09 | -2,46 | 0,014 | 0,60 | 0,94 | 0 | 250 | 0,019 | IL-4  | 0,70 | 0,09 | -2,68 | 0,007 | 0,55 | 0,91 | 0 | 250 | 0,019 |
| IL-15 | 1,61 | 0,18 | 4,27  | 0,000 | 1,29 | 2,01 | 0 | 250 | 0,000 | IL-15 | 1,37 | 0,18 | 2,31  | 0,021 | 1,05 | 1,78 | 0 | 250 | 0,045 |
| INFg  | 1,49 | 0,37 | 1,60  | 0,110 | 0,91 | 2,43 | 0 | 250 | 0,134 | INFg  | 1,81 | 0,49 | 2,19  | 0,029 | 1,06 | 3,09 | 0 | 250 | 0,058 |
| TFNa  | 1,32 | 0,10 | 3,85  | 0,000 | 1,15 | 1,52 | 0 | 250 | 0,000 | TFNa  | 1,15 | 0,09 | 1,81  | 0,071 | 0,99 | 1,34 | 0 | 250 | 0,116 |

**Table E4:** Multivariate generalized linear model with a gamma distribution (log-link) showing the arithmetic mean ratios (AMR) for the association between viremia and different laboratory and immunological parameters unadjusted and adjusted by Age, Sex, major comorbidities (Obesity, Hypertension, Type II Diabetes, Cardiovascular disease, Asthma, Dyslipidemia) and disease severity category (outpatients, ward and ICU).

|                                       | Healthy Controls (0) | Outpatients (1)     | Ward (2)         | ICU (3)              | <i>p</i> (0 vs 1) | <i>p</i> (0 vs 2) | <i>p</i> (0 vs 3) | <i>p</i> (1 vs 2) | <i>p</i> (1 vs 3) | <i>p</i> (2 vs 3) |
|---------------------------------------|----------------------|---------------------|------------------|----------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|
| <b>G-CSF (pg/ml)</b>                  | 6.90<br>[7.67]       | 23.55<br>[20.48]    | 31.95<br>[42.85] | 36.25<br>[53.35]     | < 0.001           | < 0.001           | < 0.001           | ns                | 0.034             | ns                |
| <b>IL-1<math>\beta</math> (pg/ml)</b> | 0.44<br>[1.65]       | 0.16<br>[0.30]      | 0.44<br>[0.53]   | 0.38<br>[0.51]       | ns                | ns                | ns                | < 0.001           | 0.001             | ns                |
| <b>IL-10 (pg/ml)</b>                  | 1.59<br>[0.48]       | 4.19<br>[6.68]      | 9.11<br>[10.14]  | 17<br>[22.25]        | < 0.001           | < 0.001           | < 0.001           | 0.011             | < 0.001           | 0.004             |
| <b>IL17A (pg/ml)</b>                  | 1.95<br>[1.08]       | 2.38<br>[1.45]      | 2.32<br>[1.44]   | 3.06<br>[2.87]       | ns                | ns                | 0.004             | ns                | ns                | ns                |
| <b>GM-CSF (pg/ml)</b>                 | 0.66<br>[0.42]       | 1.07<br>[0.54]      | 1.10<br>[0.67]   | 1.62<br>[1.01]       | 0.009             | 0.004             | 0.001             | ns                | < 0.001           | < 0.001           |
| <b>IL-7 (pg/ml)</b>                   | 1.81<br>[1.49]       | 2.04<br>[3.12]      | 3.19<br>[4.19]   | 4.84<br>[5.17]       | ns                | 0.020             | < 0.001           | ns                | 0.001             | ns                |
| <b>CXCL-10 (pg/ml)</b>                | 91.9<br>[71.85]      | 470.50<br>[731.50]  | 977.50<br>[943]  | 1609.50<br>[1693.75] | < 0.001           | < 0.001           | < 0.001           | < 0.001           | < 0.001           | 0.004             |
| <b>IL-1ra (pg/ml)</b>                 | 478<br>[1159.75]     | 653.50<br>[1039.25] | 1796<br>[1896]   | 1634<br>[4472.50]    | ns                | 0.004             | 0.050             | 0.011             | 0.011             | ns                |
| <b>IL-6 (pg/ml)</b>                   | 1.27<br>[0.83]       | 6.34<br>[12.42]     | 33.25<br>[48.10] | 105.50<br>[252.23]   | < 0.001           | < 0.001           | < 0.001           | < 0.001           | < 0.001           | < 0.001           |
| <b>CCL2 (pg/ml)</b>                   | 103.50<br>[39]       | 189<br>[157.50]     | 283.50<br>[304]  | 490<br>[881.75]      | < 0.001           | < 0.001           | < 0.001           | ns                | < 0.001           | < 0.001           |
| <b>IL-12p70 (pg/ml)</b>               | 0.62<br>[0.71]       | 1.46<br>[0.67]      | 1.51<br>[0.71]   | 1.36<br>[0.94]       | < 0.001           | < 0.001           | 0.001             | ns                | ns                | ns                |
| <b>IL-2 (pg/ml)</b>                   | 0.02<br>[0.09]       | 0.53<br>[0.39]      | 0.49<br>[0.57]   | 0.63<br>[0.83]       | < 0.001           | < 0.001           | < 0.001           | ns                | ns                | ns                |
| <b>IL-4 (pg/ml)</b>                   | 0.13<br>[0.27]       | 0.33<br>[0.34]      | 0.33<br>[0.39]   | 0.29<br>[0.37]       | 0.009             | 0.026             | ns                | ns                | ns                | ns                |
| <b>IL-15 (pg/ml)</b>                  | 2.11<br>[0.54]       | 3.85<br>[3.7]       | 4.89<br>[2.90]   | 8.38<br>[5.19]       | < 0.001           | < 0.001           | < 0.001           | ns                | < 0.001           | < 0.001           |
| <b>INF<math>\gamma</math> (pg/ml)</b> | 0.68<br>[0.45]       | 4.35<br>[14.16]     | 7.42<br>[15.13]  | 3.44<br>[8.50]       | < 0.001           | < 0.001           | < 0.001           | ns                | ns                | ns                |
| <b>TNF<math>\alpha</math> (pg/ml)</b> | 5.11<br>[1.79]       | 10.60<br>[4.18]     | 13<br>[6.46]     | 12.95<br>[10.34]     | < 0.001           | < 0.001           | < 0.001           | 0.011             | 0.011             | ns                |

**Table E5:** Immunological mediators' levels across severity groups.